<DOC>
	<DOCNO>NCT02222714</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics ( PK ) preliminary efficacy multiple ascend intravenous dos 3K3A-APC , Recombinant Variant Human activate protein C ( APC ) , treatment acute ischemic stroke follow treatment recombinant tissue plasminogen activator ( tPA ) , mechanical thrombectomy .</brief_summary>
	<brief_title>Safety Evaluation 3K3A-APC Ischemic Stroke</brief_title>
	<detailed_description>This multicenter , prospective , randomize , control , double-blinded Phase 2 study intend evaluate safety , PK preliminary efficacy 3K3A-APC follow treatment tPA , mechanical thrombectomy subject moderate severe acute ischemic stroke . Approximately 115 subject randomize , include planned 88 subject group four either 3K3A-APC placebo ( 3:1 ratio ) additional placebo subject enrol safety review pause . This study utilize modify version continual reassessment method ( CRM ) order establish maximum tolerate dose ( MTD ) . Eligible subject receive 3K3A-APC placebo every 12 hour 5 dos ( approximately 3 day ) , discharge hospital , whichever occur first . Subjects monitor safety evaluation Day 7 ( discharge , early ) expect see Day 7 , 14 , 30 90 safety outcome evaluation .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Acute ischemic stroke Able receive IV tPA , mechanical thrombectomy National Institutes Health Stroke Scale ( NIHSS ) score ≥ 5 Signed inform consent Mechanical thrombectomy subject : onset time arterial puncture time &lt; 6 hour History stroke penetrate head injury within 90 day prior enrollment History previous current diagnosis intracranial hemorrhage represent potential rehemorrhage subject thrombolytic therapy mechanical thrombectomy Moyamoya disease , cerebral arteriovenous malformation ( AVM ) , know unsecured aneurysm require intervention acute study period Presence neurological nonneurological comorbidities may lead , independently current stroke , deterioration subject 's neurological status trial period Presence premorbid neurological deficit functional limitation assess retrospective Modified Rankin Scale ( mRS ) score ≥ 2 Mechanical thrombectomy subject : baseline noncontrast CT scan reveal large core occlusion define local protocol Prolonged prothrombin time ( PT ) aPTT Severe hypertension hypotension Glomerular filtration rate ( GFR ) &lt; 35 mL/min Blood glucose concentration &lt; 50 mg/dL Prior exposure exogenous form APC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ischemic stroke</keyword>
	<keyword>stroke</keyword>
	<keyword>APC</keyword>
	<keyword>3K3A</keyword>
	<keyword>3K3A-APC</keyword>
	<keyword>activate protein C</keyword>
	<keyword>RHAPSODY</keyword>
</DOC>